Atyr PHARMA (NASDAQ:ATYR) Issues Earnings Results

Atyr PHARMA (NASDAQ:ATYR) announced its earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05, Zacks reports.

Atyr PHARMA Price Performance

ATYR stock traded up $0.44 during mid-day trading on Thursday, hitting $3.99. The company had a trading volume of 1,826,496 shares, compared to its average volume of 1,288,022. The company has a 50-day moving average price of $3.65 and a 200 day moving average price of $3.04. Atyr PHARMA has a 12-month low of $1.42 and a 12-month high of $4.66. The company has a market capitalization of $334.93 million, a price-to-earnings ratio of -4.24 and a beta of 0.98. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating on the stock. Finally, Leerink Partners assumed coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.